169 related articles for article (PubMed ID: 1706136)
21. [Changes in serum prostate specific antigen and testosterone levels after chlormadinone acetate treatment in patients with benign prostatic hyperplasia : a prospective multicenter clinical study].
Fujimoto K; Hirao Y; Ohashi Y; Shibata Y; Fuji K; Tsuji H; Shimizu N; Miyazawa K; Nagata M; Ohtani N; Furuya R; Boku E
Hinyokika Kiyo; 2011 Apr; 57(4):177-83. PubMed ID: 21646847
[TBL] [Abstract][Full Text] [Related]
22. [Clinical evaluation of chlormadinone acetate (CMA) in benign prostatic hypertrophy (author's transl)].
Fujisawa S; Fujii M; Yasui H; Koshito K; Kamiryo Y
Horumon To Rinsho; 1981 Nov; 29(11):1389-94. PubMed ID: 6176374
[No Abstract] [Full Text] [Related]
23. The effects of osaterone acetate on clinical signs and prostate volume in dogs with benign prostatic hyperplasia.
Socha P; Zduńczyk S; Tobolski D; Janowski T
Pol J Vet Sci; 2018 Dec; 21(4):559-566. PubMed ID: 30605276
[TBL] [Abstract][Full Text] [Related]
24. Efficacies of osaterone and delmadinone in the treatment of benign prostatic hyperplasia in dogs.
Albouy M; Sanquer A; Maynard L; Eun HM
Vet Rec; 2008 Aug; 163(6):179-83. PubMed ID: 18689779
[TBL] [Abstract][Full Text] [Related]
25. [Fundamental and clinical study on antiandrogens--androgen-dependency of prostatic tumors and clinical application of antiandrogens (author's transl)].
Shida K
Horumon To Rinsho; 1980 Aug; 28(8):899-928. PubMed ID: 6161722
[No Abstract] [Full Text] [Related]
26. [Clinical experience with oxendolone for treatment of benign prostatic hyperplasia. Clinical efficacy and effects on serum lipid and lipoprotein fraction levels].
Yasukawa A; Nihira H; Matsuki S; Fujii M; Fujiwara H; Kitano T; Kodama M; Ukai R; Tado O; Sagami K
Hinyokika Kiyo; 1984 Apr; 30(4):537-43. PubMed ID: 6207714
[TBL] [Abstract][Full Text] [Related]
27. [Application of antiandrogens on prostatic diseases].
Takahashi S; Hasegawa F; Isurugi K
Nihon Rinsho; 1994 Mar; 52(3):809-14. PubMed ID: 7513031
[TBL] [Abstract][Full Text] [Related]
28. Preoperative administration of chlormadinone acetate reduces blood loss associated with transurethral resection of the prostate: a prospective randomized study.
Ukimura O; Kawauchi A; Kanazawa M; Miyashita H; Yoneda K; Kojima M; Nakanouchi T; Miki T;
BJU Int; 2005 Jul; 96(1):98-102. PubMed ID: 15963129
[TBL] [Abstract][Full Text] [Related]
29. [Clinical evaluation of the long-term treatment with chlormadinone acetate in patients with benign prostatic hypertrophy].
Kogawa T; Yanagiya H; Takashima T; Higashino I; Kudo T; Suzuki T; Mikuni T; Kido K; Tsukui A; Yagihashi Y
Hinyokika Kiyo; 1993 Mar; 39(3):281-7. PubMed ID: 7685143
[TBL] [Abstract][Full Text] [Related]
30. [Clinical efficacy of oxendolene (antiandrogen) and bunazosin hydrochloride (alpha-adrenergic blocker) in the treatment of prostatism--comparative study of oxendolone, bunazocin hydrochloride and their combination].
Kumamoto Y; Tsukamoto T; Takagi Y; Furuya S; Yokoyama E; Takatsuka K; Tamiya T; Miyamoto S; Aoyama T; Honma A
Hinyokika Kiyo; 1987 Nov; 33(11):1921-41. PubMed ID: 2451412
[TBL] [Abstract][Full Text] [Related]
31. Comparison of the effects of chlormadinone acetate-pellet implantation and orchidectomy on benign prostatic hypertrophy in the dog.
Kawakami E; Tsutsui T; Shimizu M; Orima H; Fujita M; Ogasa A
Int J Androl; 1995 Oct; 18(5):248-55. PubMed ID: 8567095
[TBL] [Abstract][Full Text] [Related]
32. Histological evaluation of benign prostatic hyperplasia treated by long-term administration of chlormadinone acetate (CMA).
Harada M; Kinoshita Y; Moriyama M; Kondo I; Nakahashi M; Kumagai H; Sasaki K; Hosaka M
Prostate; 1994 Sep; 25(3):147-55. PubMed ID: 7520578
[TBL] [Abstract][Full Text] [Related]
33. [Study of clinical usefulness of an antiandrogen, TZP-4238, as a drug for treatment of benign prostatic hypertrophy--its influence on sexual function].
Kumamoto Y; Tsukamoto T; Aoki M; Sato Y; Umehara T; Yoshida O; Arai Y; Kubo T; Aoki H; Komatsu Y
Hinyokika Kiyo; 1994 Aug; 40(8):745-59. PubMed ID: 7524291
[TBL] [Abstract][Full Text] [Related]
34. [Clinical effects of chlormadinone acetate (CMA) on human benign prostatic hypertrophy--comparative study with hexestrol by a double blind trial (author's transl)].
Shida K; Kondo A; Takai S; Sato S; Shimazaki J
Horumon To Rinsho; 1979 Oct; 27(10):1159-72. PubMed ID: 92377
[No Abstract] [Full Text] [Related]
35. [Clinical effects of allylestrenol on benign prostatic hypertrophy by double-blind method].
Shida K; Koyanagi T; Kawakura K; Nishida T; Kumamoto Y; Orikasa S; Sato S; Takeda M; Yamanaka H; Shimazaki J
Hinyokika Kiyo; 1986 Apr; 32(4):625-48. PubMed ID: 2426932
[TBL] [Abstract][Full Text] [Related]
36. Immunohistochemical studies in canine prostatic hyperplasia--effect of antiandrogen.
Murakoshi M; Ikeda R; Tagawa M; Nakayama T
Tokai J Exp Clin Med; 1999 Jun; 24(2):77-83. PubMed ID: 10641996
[TBL] [Abstract][Full Text] [Related]
37. Effect of antiandrogen, chlormadinone acetate (CMA), in canine spontaneous benign prostatic hyperplasia (BPH).
Murakoshi M; Ikada R; Tagawa M; Nakayama T
Tokai J Exp Clin Med; 2000 Apr; 25(1):11-4. PubMed ID: 11023050
[TBL] [Abstract][Full Text] [Related]
38. Immunolocalization of androgen receptor in canine prostatic hyperplasia--effect of antiandrogen.
Murakoshi M; Ikeda R; Tagawa M; Nakayama T; Honma S; Mieda M
Tokai J Exp Clin Med; 1998 Nov; 23(5):209-12. PubMed ID: 10418722
[TBL] [Abstract][Full Text] [Related]
39. Anti-androgen TSAA-291. I. Anti-androgenic effects of a new steroid TSAA-291 (16 beta-ethyl-17 beta-hydroxy-4-oestren-3-one) and its derivatives.
Nakayama R; Masuoka M; Masaki T; Shimamoto K
Acta Endocrinol Suppl (Copenh); 1979; 229():2-23. PubMed ID: 93380
[TBL] [Abstract][Full Text] [Related]
40. Prostate-specific antigen changes as a result of chlormadinone acetate administration to patients with benign prostatic hyperplasia: a retrospective multi-institutional study.
Fujimoto K; Hirao Y; Masumori N; Arai Y; Yamanaka H; Kato T; Miyazawa K
Int J Urol; 2006 May; 13(5):543-9. PubMed ID: 16771723
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
